Amarin details primary endpoint data for Vascepa, addresses placebo concern

Amarin Corp. plc. (NASDAQ:AMRN) presented detailed primary endpoint data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) and addressed concerns that the mineral oil used in the trial's placebo arm may have affected the results.

The data were presented at the American Heart Association meeting in Chicago and published in the

Read the full 594 word article

User Sign In